Since genetic targeting of S100A9 in mice limits MDSC expansion and sepsis-associated immunosuppression, molecular targeting of Hotairm1 is a plausible drug target for reversing sepsis-induced chronic immunosuppression. This evidence concerns the gene HOTAIRM1 and Sepsis.